Global Interferon Market Outlook 2022

Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of several pathogens, such as viruses, bacteria, parasites, and also tumor cells. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
In Asia-Pacific, Interferon key players include Roche, Anke Biotechnology, Tri-Prime, etc. Asia-Pacific top three manufacturers hold a share about 40%.
In terms of product, Long-lasting Type is the largest segment of Cobalt, with a share about 90%. And in terms of application, the largest application is Hepatitis, followed by Multiple Sclerosis.

The global Interferon market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Interferon volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Interferon market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Interferon Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Long-lasting Type
Ordinary Type

Segment by Application
Hepatitis
Multiple Sclerosis
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Roche
Anke Biotechnology
Bayer
Merck & Co
Tri-Prime
Kawin
Genzon Pharma
Novartis
Biogen
Merck KGaA
Zydus Cadila
Huaxin Biotechnology
Harbin Pharmaceutical